SCHEMBL968958

SCHEMBL968958

C=CC(=O)OC(C)COP(=O)(O)OCC[N+](C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.36
TSHR P16473 3/20 0.35
ADRA1D P25100 1/20 0.33
PTAFR P25105 1/20 0.33
HTR1D P28221 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1B P35368 1/20 0.33
DRD3 P35462 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
NR5A2 O00482 1/20 0.32
NR5A1 Q13285 1/20 0.32
CHRM2 P08172 2/20 0.32
CHRM4 P08173 2/20 0.32
CHRM1 P11229 2/20 0.32
TBXA2R P21731 1/20 0.32
MAPT P10636 2/20 0.31
PLA2G10 O15496 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM3 P20309 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7878849 0.87 TSHR (0.44) TSHR
SCHEMBL2120609 0.85 SMN1; SMN2 (0.53) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
SCHEMBL27055217 0.83 TSHR (0.44) FABP3TSHR
SCHEMBL28126982 0.82 SMN1; SMN2 (0.34) FABP3SMN1; SMN2TSHRADRA1DPTAFR
SCHEMBL28093839 0.82 FABP3 (0.38) FABP3SMN1; SMN2TSHRADRA1DPTAFR
SCHEMBL28853370 0.81 FABP3 (0.45) FABP3SMN1; SMN2TSHRADRA1DPTAFR
SCHEMBL27983078 0.80 TSHR (0.41) TSHR
SCHEMBL28572562 0.79 FABP3 (0.34) FABP3SMN1; SMN2TSHRADRA1DPTAFR
SCHEMBL6673980 0.79 BTN3A1 (0.40) TSHR
SCHEMBL2942450 0.79 TSHR (0.46) FABP3SMN1; SMN2TSHRCHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104119479-B Biomimetic amphiphilic graft copolymer with cell membrane structure and preparation method thereof 四川大学 2017-01-18 CN disclosed
US-8956602-B2 Delivery of drugs Landec, Inc. (US) 2015-02-17 US disclosed
US-8524259-B2 Systems and methods for delivery of materials LANDEC CORPORATION (US) 2013-09-03 US disclosed
US-8399007-B2 Method for formulating a controlled-release pharmaceutical formulation LANDEC CORPORATION (US) 2013-03-19 US disclosed
EP-2502619-A2 Systems and methods for delivery of materials Landec Corporation (US) 2012-09-26 EP disclosed
EP-2500015-A1 Delivery of drugs Landec Corporation (US) 2012-09-19 EP disclosed
US-20110009571-A1 SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS ALCON RESEARCH, LLC 2011-01-13 US disclosed
EP-2229150-A2 SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS LANDEC CORPORATION (US) 2010-09-22 EP disclosed
US-20100210792-A1 DRUG DELIVERY LANDEC CORPORATION 2010-08-19 US disclosed
US-20100004124-A1 Systems and methods for delivery of materials for agriculture and aquaculture LANDEC CORPORATION 2010-01-07 US disclosed
US-20090263346-A1 Systems and methods for delivery of drugs LANDEC CORPORATION 2009-10-22 US disclosed
US-20090252777-A1 Method for formulating a controlled-release pharmaceutical formulation LANDEC CORPORATION (US) 2009-10-08 US disclosed
US-20090246155-A1 Compositions and methods for personal care LANDEC CORPORATION 2009-10-01 US disclosed
EP-2101745-A1 DELIVERY OF DRUGS LANDEC CORPORATION (US) 2009-09-23 EP disclosed
WO-2009073192-A2 SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS LANDEC CORPORATION (US) 2009-06-11 WO disclosed
US-20080269105-A1 Delivery of drugs ALCON RESEARCH, LLC 2008-10-30 US disclosed
WO-2008070118-A9 DRUG DELIVERY LANDEC CORP (US) 2008-09-18 WO disclosed
WO-2008070118-A1 DRUG DELIVERY LANDEC CORPORATION (US) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090263346-A1 Systems and methods for delivery of drugs CYCS, CTRC, PPIC FABP3 596/4885SMN1; SMN2 3647/4885TSHR 3231/4885
US-20090246155-A1 Compositions and methods for personal care PPIC, CYCS, CTRC FABP3 2168/4885SMN1; SMN2 3965/4885TSHR 3387/4885
US-20100004124-A1 Systems and methods for delivery of materials for agriculture and aquaculture CYCS, PCCA, CRYAA FABP3 901/4885SMN1; SMN2 3533/4885TSHR 4616/4885
US-20080269105-A1 Delivery of drugs ABCB11, ABCB1, LPXN FABP3 469/4885SMN1; SMN2 2086/4885TSHR 1074/4885
US-20090252777-A1 Method for formulating a controlled-release pharmaceutical formulation LPXN, CYP3A7, LIPA FABP3 1053/4885SMN1; SMN2 2379/4885TSHR 1441/4885
US-20100210792-A1 DRUG DELIVERY ABCB11, VEGFA, ABCB1 FABP3 378/4885SMN1; SMN2 1075/4885TSHR 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.